These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 23669590)

  • 21. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
    N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dermatologists' views and opinions about photo(chemo)therapy and conventional systemic psoriasis therapies: results from a Belgian survey.
    Nijsten T; Lambert J
    Dermatology; 2006; 213(2):123-33. PubMed ID: 16902289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients.
    Wan J; Abuabara K; Troxel AB; Shin DB; Van Voorhees AS; Bebo BF; Krueger GG; Callis Duffin K; Gelfand JM
    J Am Acad Dermatol; 2012 Mar; 66(3):376-86. PubMed ID: 21856040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. German psoriasis registry PsoBest: objectives, methodology and baseline data.
    Augustin M; Spehr C; Radtke MA; Boehncke WH; Luger T; Mrowietz U; Reusch M; Strömer K; Wozel G; von Kiedrowski R; Rustenbach SJ; Purwins S; Reich K
    J Dtsch Dermatol Ges; 2014 Jan; 12(1):48-57. PubMed ID: 24393314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.
    Scanlon JV; Exter BP; Steinberg M; Jarvis CI
    Ann Pharmacother; 2009 Sep; 43(9):1456-65. PubMed ID: 19671802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological treatments for moderate-to-severe psoriasis: indirect comparison.
    Galván-Banqueri M; Marín Gil R; Santos Ramos B; Bautista Paloma FJ
    J Clin Pharm Ther; 2013 Apr; 38(2):121-30. PubMed ID: 23442134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus.
    Reich K; Griffiths C; Barker J; Chimenti S; Daudén E; Giannetti A; Gniadecki R; Katsambas A; Langley R; Mrowietz U; Ogilvie A; Ortonne JP; Reider N; Saurat JH
    Dermatology; 2008; 217(3):268-75. PubMed ID: 18685261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis--a multinational cross-sectional study.
    Nast A; Mrowietz U; Kragballe K; de Jong EM; Puig L; Reich K; Warren RB; Werner R; Kopkow C; Schmitt J
    Arch Dermatol Res; 2013 Dec; 305(10):899-907. PubMed ID: 23748949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus.
    Langley RG; Saurat JH; Reich K;
    J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):373-81. PubMed ID: 22151734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide.
    van Muijen ME; van der Schoot LS; van den Reek JMPA; de Jong EMGJ
    Arch Dermatol Res; 2022 Sep; 314(7):687-695. PubMed ID: 34467442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survey on the Management of Dysplastic Nevus by Dermatologists in the Center-Spain section of the Spanish Academy of Dermatology and Venereology (AEDV).
    Baeza-Hernández G; Rubio-Aguilera RF; Martínez-Morán C; Álvarez-Garrido H; Garrido-Ríos AA; Borbujo J
    Actas Dermosifiliogr; 2023; 114(10):850-857. PubMed ID: 37482291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Home ultraviolet B phototherapy for psoriasis: discrepancy between literature, guidelines, general opinions and actual use. Results of a literature review, a web search, and a questionnaire among dermatologists.
    Koek MB; Buskens E; Bruijnzeel-Koomen CA; Sigurdsson V
    Br J Dermatol; 2006 Apr; 154(4):701-11. PubMed ID: 16536814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in older adult psoriasis outpatient health care practices in the United States.
    Wong JW; Davis SA; Feldman SR; Koo JY
    J Drugs Dermatol; 2012 Aug; 11(8):957-62. PubMed ID: 22859241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.
    Rustin MH
    Br J Dermatol; 2012 Nov; 167 Suppl 3():3-11. PubMed ID: 23082810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey.
    Schots L; Grine L; Soenen R; Lambert J
    J Dermatolog Treat; 2022 May; 33(3):1473-1481. PubMed ID: 33019835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
    Inzinger M; Heschl B; Weger W; Hofer A; Legat FJ; Gruber-Wackernagel A; Tilz H; Salmhofer W; Quehenberger F; Wolf P
    Br J Dermatol; 2011 Sep; 165(3):640-5. PubMed ID: 21564068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis.
    Abuabara K; Wan J; Troxel AB; Shin DB; Van Voorhees AS; Bebo BF; Krueger GG; Callis Duffin K; Gelfand JM
    J Am Acad Dermatol; 2013 Feb; 68(2):262-9. PubMed ID: 22910105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists.
    Gyulai R; Bagot M; Griffiths CEM; Luger T; Naldi L; Paul C; Puig L; Kemény L
    J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):224-231. PubMed ID: 24731093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
    Carretero G; Ribera M; Belinchón I; Carrascosa JM; Puig L; Ferrandiz C; Dehesa L; Vidal D; Peral F; Jorquera E; González-Quesada A; Muñoz C; Notario J; Vanaclocha F; Moreno JC;
    Actas Dermosifiliogr; 2013 Sep; 104(7):598-616. PubMed ID: 23891453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.